Faculty profile

Martin Gleave

ResearcherUrologic SciencesUniversity of British Columbia

This profile is built from public research funding records (CIHR, NSERC and SSHRC) and PubMed. We have not imported them from a University of British Columbia directory, so their courses may be missing. Find their university profile.

Martin Gleave

Researcher

Urologic Sciences

Health Sciences

University of British Columbia

Vancouver, British Columbia, Canada

Supervision signals

Has led research grants, which requires an independent research appointment. Ask their department whether they supervise graduate students.
60 publications in the last five years, latest in 2026.
Senior (last) author on 2 recent papers, a sign of leading a research group.
Principal investigator on 12 research grants (7 CIHR, 3 NSERC, 2 SSHRC), most recently in 2020.
Supervised 1 trainee who won CIHR awards, most recently in 2010.

These signals come from public records, including CIHR, NSERC and SSHRC funding decisions. Ask the professor or the graduate program whether they are taking new students.

Academic metrics

195

Publications

5,914

Citations

h-index

Collaborators

Grants

Publications by year

Counts cover the works listed on the university profile; citation counts come from Dimensions.

Profiles and links

Search on Google Scholar

Find them onX · LinkedIn · Bluesky · YouTube

Signals and details

Research

Prostate Cancer Small Molecule Inhibitors Hoxb13 Transcriptional Regulation Androgen Receptor Binding Function-3 Animal Models Biochemistry

Latest papers

Phase Ib Trial of Bavdegalutamide (ARV-110) in Combination with Abiraterone for Metastatic Prostate Cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research · 2026
Perioperative Apalutamide in High-Risk Localized Prostate Cancer.
The New England journal of medicine · 2026
A Phase 2, Randomized, Controlled Trial of Best Systemic Therapy Versus Best Systemic Therapy with Definitive Treatment of the Primary Tumor in Metastatic Prostate Cancer.
European urology · 2026

All 195 publications

Latest funding

Derisking the Development of VPC-25959 Derivatives as Novel MCT4 Inhibitors for Clinical Trials in Patients with Advanced Glycolytic Cancers
CIHR · 2026 · Co-investigator
$1,912,500
PROX1 Drives Cell Lineage Reprogramming in Neuroendocrine Prostate Cancer
CIHR · 2025 · Co-investigator
$1,166,625
Stimulated Raman Histology for Real-Time Identification and Risk Stratification of Prostate Cancer
CIHR · 2025 · Co-investigator
$887,400

All 35 grants and awards

From the 150 most recent of 195 publications.

Phase Ib Trial of Bavdegalutamide (ARV-110) in Combination with Abiraterone for Metastatic Prostate Cancer.

Smoragiewicz M, Bernard-Tessier A, Linch M, Shen J, Shore ND, Parikh O, Chi KN, Sokolova AO, Culine S, McKean M, Gleave M, Devitt ME, Zhi E, Gong J, Landrette S, Colasanto M, Patel V, Gao X

Clinical cancer research : an official journal of the American Association for Cancer Research2026

DOI: 10.1158/1078-0432.ccr-26-0253 PMID: 42227954

Perioperative Apalutamide in High-Risk Localized Prostate Cancer.

Taplin ME, Gleave M, Shore ND, Lopez-Gitlitz A, Kretschmer A, Efstathiou E, Nguyen PL, Damião R, Kamoto T, Ross A, Briganti A, Hadaschik BA, Heidenreich A, Juárez Soto Á, Ye H, Gotto G, Rooney B, Tian SK, Wetherhold L, Miladinovic B, McCarthy SA, Evans CP, Kibel AS, PROTEUS Investigators

The New England journal of medicine2026

DOI: 10.1056/nejmoa2603878 PMID: 42223077

A Phase 2, Randomized, Controlled Trial of Best Systemic Therapy Versus Best Systemic Therapy with Definitive Treatment of the Primary Tumor in Metastatic Prostate Cancer.

Chapin BF, Smaldone M, Zurita AJ, Wang J, Cooperberg MR, Gleave M, Delacroix SE, Davis J, Pettaway C, Pisters L, Adibi M, Chery L, Papadopoulos J, Ward J, Gregg J, Navai N, Corn P, Subudhi SK, Logothetis C, Kuban D, Nguyen Q, Tang C, Choi S, Hoffman K, Lozano M, Elsheftawi M, Achim M, Zhao Y, Ramesh N, Sei E, Navin N, Nogueras Gonzalez GM, Wang X, Zhu K, Troncoso P, Zhang M, McGuire S, Aparicio AM

European urology2026

DOI: 10.1016/j.eururo.2026.02.011 PMID: 41833492

How enzalutamide affects sex life and how taking a break from treatment affects quality of life: a plain language summary of results from the EMBARK study in people with hormone-sensitive prostate cancer and high-risk biochemical recurrence.

Freedland SJ, De Giorgi U, Rannikko A, Saad F, Gleave M, Ramírez Backhaus M, Mulhall J, Pandya BJ, Ivanova J, Kral P, Turnbull J, Shore N

Future oncology (London, England)2026

DOI: 10.1080/14796694.2026.2691257 PMID: 42402863

Reply by Authors.

Shore ND, Gleave M, De Giorgi U, Rannikko A, Pieczonka CM, Sridharan S, Brasso K, Woo HH, Gómez Caamaño A, Saranchuk JW, Nordquist LT, Ferreira U, Tang Y, Rosbrook B, Haas GP, Rosales M, Zohren F, Tarazi J, Freedland SJ

The Journal of urology2026

DOI: 10.1097/ju.0000000000004961 PMID: 41650344

Automating standardization of prostate cancer biopsy and histopathology reports with privacy-preserving local large language models.

Malyala R, Namekawa T, Black A, Gleave M, Mannas M

Urologic oncology2026

DOI: 10.1016/j.urolonc.2026.05.029 PMID: 42322812

Reply by Authors.

The Journal of urology2026

DOI: 10.1097/ju.0000000000004962 PMID: 41650342

Treatment of High-Risk Biochemically Recurrent Prostate Cancer With Enzalutamide in Combination With Leuprolide: Secondary End Points From the EMBARK Trial.

The Journal of urology2026

DOI: 10.1097/ju.0000000000004890 PMID: 41364813

Prognostic Significance of the Cytoplasmic Expression of UDP-glucuronosyltransferase 2B17 in Localized Prostate Cancer: Insights from the Canadian Prostate Cancer Biomarker Network and PROCURE Multi-institutional Cohorts.

Uchil A, Lacombe L, Hovington H, Brisson H, Simonyan D, Caron P, Ouellet V, Latour M, Aprikian A, Bergeron A, Chevalier S, McKercher G, Brimo F, Fazli L, Fleshner N, Gleave M, Karakiewicz PI, Carmel M, Hamilou Z, Trudel D, van der Kwast T, Mes-Masson AM, Dong X, Saad F, Guillemette C, Lévesque E

European urology oncology2026

DOI: 10.1016/j.euo.2025.07.014 PMID: 40998686

Radiotherapy- Versus Surgery-based Treatment Strategy in High-risk Prostate Cancer.

Roy S, Sun Y, Eastham JA, Gleave M, Wallis CJD, Beltran HA, Kishan AU, Jia AY, Zaorsky NG, Nagar H, Garcia JA, Small EJ, Nguyen P, Attard G, McKay RR, Sartor O, Berlin A, Rosenthal SA, Halabi S, Vince R, Ponsky L, Morgan SC, Hannan R, Raben A, Roach M, Michalski JM, Morris MJ, Sandler HM, Spratt DE

European urology oncology2026

DOI: 10.1016/j.euo.2025.06.009 PMID: 40683825

Something wrong or missing on this profile? Suggest a correction

Martin Gleave

Research

Latest papers

Latest funding

Phase Ib Trial of Bavdegalutamide (ARV-110) in Combination with Abiraterone for Metastatic Prostate Cancer.

Perioperative Apalutamide in High-Risk Localized Prostate Cancer.

A Phase 2, Randomized, Controlled Trial of Best Systemic Therapy Versus Best Systemic Therapy with Definitive Treatment of the Primary Tumor in Metastatic Prostate Cancer.

How enzalutamide affects sex life and how taking a break from treatment affects quality of life: a plain language summary of results from the EMBARK study in people with hormone-sensitive prostate cancer and high-risk biochemical recurrence.

Reply by Authors.

Automating standardization of prostate cancer biopsy and histopathology reports with privacy-preserving local large language models.

Reply by Authors.

Treatment of High-Risk Biochemically Recurrent Prostate Cancer With Enzalutamide in Combination With Leuprolide: Secondary End Points From the EMBARK Trial.

Prognostic Significance of the Cytoplasmic Expression of UDP-glucuronosyltransferase 2B17 in Localized Prostate Cancer: Insights from the Canadian Prostate Cancer Biomarker Network and PROCURE Multi-institutional Cohorts.

Radiotherapy- Versus Surgery-based Treatment Strategy in High-risk Prostate Cancer.

Frequent collaborators

Yuzhuo Wang

Amina Zoubeidi

Xuesen Dong

Alan So

Colin Collins

Kim Chi

Lucia Nappi

Artem Cherkasov

Antonio Finelli

Larry Goldenberg

Neil Fleshner

Ralph Buttyan

Eric Vigneault

Bobby Shayegan

Nawaid Usmani

Christopher Ong

Yemin Wang

Alejandro Berlin

Scott Tyldesley

Mads Daugaard

Septimiu Salcudean

Peter Black

Michael Cox

Marianne Koritzinsky

Paul Rennie

Chantal Guillemette

David Huntsman

Richard Sowery

Gang Wang

Miles Mannas

Andrew Loblaw

David Uehling

Arnim Pause

Michael Pollak

Cenk Sahinalp

Colin Collins

Victor Ling

Eldad Zacksenhaus

Isabella Caniggia

Xiaoyan Jiang